Compare HCSG & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCSG | IMCR |
|---|---|---|
| Founded | 1976 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Assisted Living Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 1994 | 2016 |
| Metric | HCSG | IMCR |
|---|---|---|
| Price | $21.59 | $34.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | $22.67 | ★ $66.33 |
| AVG Volume (30 Days) | ★ 816.7K | 456.6K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.83 | 30.39 |
| EPS | ★ 0.69 | 0.23 |
| Revenue | ★ $1,837,173,000.00 | $249,428,000.00 |
| Revenue This Year | $7.39 | $14.57 |
| Revenue Next Year | $5.22 | $8.21 |
| P/E Ratio | ★ $30.57 | $148.70 |
| Revenue Growth | 7.08 | ★ 43.05 |
| 52 Week Low | $15.04 | $27.56 |
| 52 Week High | $25.75 | $40.71 |
| Indicator | HCSG | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 54.55 |
| Support Level | $21.08 | $30.48 |
| Resistance Level | $22.83 | $35.73 |
| Average True Range (ATR) | 0.70 | 1.24 |
| MACD | -0.24 | -0.09 |
| Stochastic Oscillator | 29.01 | 66.77 |
Healthcare Services Group Inc is a provider of housekeeping and facility management services to the healthcare industry. The company manages and evaluates its operations in two reportable segments: Environmental Services segment includes housekeeping, management of clients' housekeeping departments, cleaning, disinfecting and sanitizing, laundry, bed linen, and uniform services, linen and other services; and Dietary Segment includes dietary department services, food purchasing, meal preparation, and providing dietitian consulting services. Its clients are nursing homes, retirement complexes, rehabilitation centers, and hospitals in the United States of America. The Environmental Services segment derives maximum revenue.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.